LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

2.93 6.16

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.76

Máximo

2.96

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+638.01% upside

Dividendos
By Dow Jones
Próximas Ganancias	2 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-139M 250M
Apertura anterior	-3.23
Cierre anterior	2.93

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

290 / 344 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 may 2026, 21:33 UTC

Ganancias

Correction to Salesforce 1Q Sales, Profit Rise Article

27 may 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 may 2026, 20:18 UTC

Ganancias

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 may 2026, 23:49 UTC

Charlas de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 may 2026, 23:39 UTC

Charlas de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 may 2026, 23:08 UTC

Charlas de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 may 2026, 22:21 UTC

Charlas de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 may 2026, 21:29 UTC

Acciones populares

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 may 2026, 21:08 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 may 2026, 21:02 UTC

Ganancias

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 may 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 may 2026, 20:55 UTC

Ganancias

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 may 2026, 20:48 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 may 2026, 20:45 UTC

Ganancias

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 may 2026, 20:34 UTC

Adquisiciones, fusiones, absorciones

Webster Financial Stockholders Approve Sale to Banco Santander

27 may 2026, 20:32 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 may 2026, 20:30 UTC

Ganancias

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 may 2026, 20:30 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 may 2026, 20:22 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:16 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 may 2026, 20:13 UTC

Ganancias

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

638.01% repunte

Estimación a 12 Meses

Media 20 USD 638.01%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

290 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.